Chronic Rhinosinusitis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chronic Rhinosinusitis - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Rhinosinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Rhinosinusitis: Overview
Chronic rhinosinusitis refers to a condition that lasts at least 12 weeks, despite attempts to treat it, and causes at least two of the following symptoms: Nasal congestion; Mucus discharge from the nose or mucus that drips down the back of the throat; Facial pain, pressure, or 'fullness'; or a decreased sense of smell. Chronic rhinosinusitis is different from the more common form of rhinosinusitis (called acute rhinosinusitis), which is a temporary infection of the sinuses that often occurs following colds. Unlike acute rhinosinusitis, which is usually caused by infection, chronic rhinosinusitis often has more complicated and elusive causes. Infections can certainly contribute to or worsen chronic rhinosinusitis, but people with the chronic condition usually have long-standing inflammation that cannot be explained by infection alone.
'Chronic Rhinosinusitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinusitis pipeline landscape is provided which includes the disease overview and Chronic Rhinosinusitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Rhinosinusitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic Rhinosinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Rhinosinusitis Emerging Drugs
Further product details are provided in the report……..
Chronic Rhinosinusitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Rhinosinusitis drugs segregated based on following parameters that define the scope of the report, such as:
Chronic Rhinosinusitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Rhinosinusitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Rhinosinusitis drugs.
Chronic Rhinosinusitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic Rhinosinusitis - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Rhinosinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Rhinosinusitis: Overview
Chronic rhinosinusitis refers to a condition that lasts at least 12 weeks, despite attempts to treat it, and causes at least two of the following symptoms: Nasal congestion; Mucus discharge from the nose or mucus that drips down the back of the throat; Facial pain, pressure, or 'fullness'; or a decreased sense of smell. Chronic rhinosinusitis is different from the more common form of rhinosinusitis (called acute rhinosinusitis), which is a temporary infection of the sinuses that often occurs following colds. Unlike acute rhinosinusitis, which is usually caused by infection, chronic rhinosinusitis often has more complicated and elusive causes. Infections can certainly contribute to or worsen chronic rhinosinusitis, but people with the chronic condition usually have long-standing inflammation that cannot be explained by infection alone.
'Chronic Rhinosinusitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinusitis pipeline landscape is provided which includes the disease overview and Chronic Rhinosinusitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Rhinosinusitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Rhinosinusitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Rhinosinusitis.
This segment of the Chronic Rhinosinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Rhinosinusitis Emerging Drugs
- CBP-201: Connect Biopharma
- LYR-210: Lyra Therapeutics
Further product details are provided in the report……..
Chronic Rhinosinusitis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Rhinosinusitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Rhinosinusitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic Rhinosinusitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Rhinosinusitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Rhinosinusitis drugs.
Chronic Rhinosinusitis Report Insights
- Chronic Rhinosinusitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Rhinosinusitis drugs?
- How many Chronic Rhinosinusitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Rhinosinusitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinusitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Rhinosinusitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Connect Biopharma
- Lyra Therapeutics
- Sanotize Research and Development corp.
- Regeneron Pharmaceuticals
- AstraZeneca
- Kyowa Kirin Co., Ltd.
- Keymed Biosciences Co.Ltd
- Pfizer
- GlycoMira Therapeutics
- CBP-201
- LYR-210
- Dupilumab
- Tezepelumab
- Benralizumab
- CM310
- PF-06817024
Introduction
Executive Summary
Chronic Rhinosinusitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Rhinosinusitis – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
LYR-210: Lyra Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
PF-06817024: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chronic Rhinosinusitis Key Companies
Chronic Rhinosinusitis Key Products
Chronic Rhinosinusitis- Unmet Needs
Chronic Rhinosinusitis- Market Drivers and Barriers
Chronic Rhinosinusitis- Future Perspectives and Conclusion
Chronic Rhinosinusitis Analyst Views
Chronic Rhinosinusitis Key Companies
Appendix
Executive Summary
Chronic Rhinosinusitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Rhinosinusitis – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
LYR-210: Lyra Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
PF-06817024: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chronic Rhinosinusitis Key Companies
Chronic Rhinosinusitis Key Products
Chronic Rhinosinusitis- Unmet Needs
Chronic Rhinosinusitis- Market Drivers and Barriers
Chronic Rhinosinusitis- Future Perspectives and Conclusion
Chronic Rhinosinusitis Analyst Views
Chronic Rhinosinusitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Rhinosinusitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Rhinosinusitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Rhinosinusitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Rhinosinusitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
